Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17125618 | STARCH-BASED HEMOSTATIC POWDER AND PREPARATION METHOD THEREOF | December 2020 | April 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17122182 | PROCESS FOR MAKING SUGAMMADEX | December 2020 | March 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17252265 | USE OF SALIDROSIDE AND DERIVATIVE THEREOF IN PREPARATION OF INHIBITOR MEDICAMENT FOR DISEASES OF OPHTHALMIC FIBROSIS CAUSED BY ABNORMALITIES OF EXTRACELLULAR MATRIX PROTEINS | December 2020 | June 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17051154 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT OR ANTI-VIRUS AGENT COMPRISING THE SAME | December 2020 | April 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17056552 | COMPOSITION CONTAINING FLAVONOID-CYCLODEXTRIN CLATHRATE COMPOUND | November 2020 | July 2022 | Allow | 20 | 4 | 1 | Yes | No |
| 17090182 | DRUG DELIVERY ENHANCER COMPRISING SUBSTANCE FOR ACTIVATING LYSOPHOSPHOLIPID RECEPTORS | November 2020 | November 2023 | Abandon | 36 | 1 | 0 | No | No |
| 17088234 | REGENERATION OF DISEASES INTERVERTEBRAL DISCS | November 2020 | February 2023 | Abandon | 28 | 2 | 0 | Yes | No |
| 17088000 | NUCLEIC ACID PREPARATION COMPOSITIONS AND METHODS | November 2020 | April 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17051549 | COMBINATION COMPRISING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND | October 2020 | January 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17083615 | HYDROXYPROPYL METHYL CELLULOSE ACETATE SUCCINATE AND METHOD FOR PRODUCING THE SAME | October 2020 | February 2023 | Allow | 27 | 1 | 0 | No | No |
| 17051385 | SERPIN INHIBITORS FOR THE TREATMENT OF PRION AND PRION-LIKE DISEASES | October 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17080925 | COMPOSITIONS AND METHODS FOR TREATING VAGINAL ATROPHY | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17080093 | INHIBITORS OF ENPP1 AND METHODS OF USING SAME | October 2020 | July 2023 | Abandon | 32 | 2 | 0 | No | No |
| 17049185 | CROSS-LINKED STARCH-BASED POLYMERS FOR DRUG-DELIVERY | October 2020 | March 2022 | Allow | 17 | 2 | 0 | No | No |
| 17027318 | COMPOSITIONS AND METHODS FOR DELIVERING AN AGENT TO A WOUND | September 2020 | September 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16982827 | OMNIPHILIC NANO-VESICLES BASED ON MODIFIED POLYSACCHARIDES FOR DELIVERY OF ACTIVE AGENTS | September 2020 | August 2024 | Abandon | 47 | 6 | 0 | Yes | No |
| 17003576 | FOOD OR FEED COMPOSITION FOR IMPROVING COGNITIVE FUNCTION OR MEMORY COMPRISING EXTRACT OF DESALTED SALICORNIA EUROPAEA | August 2020 | July 2022 | Abandon | 22 | 1 | 0 | No | No |
| 17003714 | USE OF SOY HULL POLYSACCHARIDE IN PREPARATION OF DRUGS FOR MODULATING INTESTINAL FLORA, REDUCING BLOOD GLUCOSE AND BLOOD LIPID, AND RESISTING INFLAMMATION, AND OF FOODS FOR SPECIAL MEDICAL PURPOSE | August 2020 | February 2024 | Abandon | 42 | 3 | 1 | Yes | No |
| 16975332 | POLYDATIN PACLITAXEL COMPOSITION, AND APPLICATION IN PREPARING MEDICAMENT FOR PREVENTING AND TREATING GASTRIC CANCER | August 2020 | November 2022 | Abandon | 26 | 2 | 0 | No | No |
| 16991284 | INACTIVATING BACTERIA WITH ELECTRIC PULSES AND ANTIBIOTICS | August 2020 | May 2021 | Allow | 9 | 1 | 0 | No | No |
| 16941225 | METHODS OF MAINTAINING OR INCREASING GROWTH OR COGNITIVE DEVELOPMENT | July 2020 | January 2023 | Abandon | 30 | 2 | 0 | No | No |
| 16938641 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | July 2020 | October 2021 | Abandon | 15 | 2 | 0 | No | No |
| 16937094 | INJECTABLE ANTIBIOTIC FORMULATIONS AND USE THEREOF | July 2020 | April 2021 | Abandon | 9 | 1 | 0 | No | No |
| 16933043 | METHODS OF TREATING GALECTIN-3 DEPENDENT DISORDERS | July 2020 | November 2023 | Abandon | 40 | 4 | 1 | No | No |
| 16961480 | THERMOPLASTIC STARCH | July 2020 | July 2021 | Allow | 12 | 2 | 0 | No | No |
| 16961248 | Method of Isolating Exosomes Using Encapsulation And Aqueous Micellar System | July 2020 | August 2022 | Allow | 25 | 0 | 0 | No | No |
| 16959804 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | July 2020 | January 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16959649 | CELLULOSE ACETATE FIBER, CELLULOSE ACETATE BAND, AND METHOD FOR PRODUCING CELLULOSE ACETATE BAND | July 2020 | July 2024 | Abandon | 48 | 1 | 1 | Yes | No |
| 16914675 | Carbopyronone Compounds Useful as Diagnostic Adjuvants | June 2020 | March 2023 | Abandon | 33 | 1 | 1 | No | No |
| 16959084 | TRITERPENOID-CONTAINING PHARMACEUTICAL COMPOSITION AND USE THEREOF | June 2020 | July 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16958553 | Extracellular Matrices, Uses thereof, and Method for Making Extracellular Matrices | June 2020 | August 2024 | Abandon | 49 | 4 | 1 | No | No |
| 16955641 | PENTOSAN POLYSULFATE AND MEDICINE CONTAINING PENTOSAN POLYSULFATE | June 2020 | February 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16904028 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | June 2020 | July 2022 | Abandon | 25 | 2 | 0 | No | Yes |
| 16892865 | BIOCOMPATIBLE AND BIOABSORBABLE DERIVATIZED CHITOSAN COMPOSITIONS | June 2020 | September 2021 | Allow | 15 | 1 | 1 | Yes | No |
| 16889474 | COMPOSITION FOR USE IN THE PREVENTION OR TREATMENT OF SALMONELLOSIS | June 2020 | August 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16881111 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | May 2020 | January 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 16764336 | STEVIA-DERIVED MOLECULES, METHODS OF OBTAINING SUCH MOLECULES, AND USES OF THE SAME | May 2020 | May 2022 | Allow | 24 | 1 | 0 | No | No |
| 16764090 | PANAXADIOL GLYCOSIDE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | May 2020 | August 2023 | Allow | 39 | 3 | 1 | No | No |
| 15930154 | COMBINATION OF NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND HISTAMINE H2 RECEPTOR ANTAGONISTS FOR VIRAL INFECTIONS | May 2020 | April 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16867302 | CELLULOSE PROCESSING | May 2020 | April 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16759366 | PATHOGEN LYSIS AND NUCLEIC ACID EXTRACTION METHOD USING ZINC OXIDE NANOSTAR | April 2020 | December 2022 | Allow | 60 | 1 | 1 | Yes | No |
| 16857538 | Hydroxypropyl Starch For Preparing Empty Capsules And Hydroxypropyl Starch-Based Soft Capsules | April 2020 | September 2022 | Allow | 29 | 2 | 1 | Yes | No |
| 16850253 | HYALURONAN CONJUGATES WITH PHARMACEUTICALLY ACTIVE SUBSTANCES, METHODS AND COMPOSITIONS | April 2020 | September 2021 | Allow | 17 | 1 | 1 | Yes | No |
| 16845636 | Novel Polymer, Preparation Method Therefor, Nanofiber Synthesized Therefrom, and Method for Fabricating Same Nanofiber | April 2020 | October 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16844091 | METHODS OF TREATING DISEASES | April 2020 | July 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16842017 | AQUEOUS ORAL SOLUTIONS OF STEROID HORMONES AND HYDROXYPROPYL-BETA-CYCLODEXTRIN WITH OPTIMISED BIOAVAILABILITY | April 2020 | September 2020 | Allow | 5 | 1 | 0 | No | No |
| 16650305 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | March 2020 | July 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16648930 | BIODEGRADABLE HYDROGEL | March 2020 | January 2023 | Abandon | 34 | 0 | 1 | No | No |
| 16648351 | IONIC POLYMERS AND USE THEREOF IN BIOMASS PROCESSING | March 2020 | October 2023 | Allow | 43 | 3 | 2 | Yes | No |
| 16646882 | REFINED BETA-GLUCAN AND METHODS OF MAINTAINING FILTERABILITY OF BETA-GLUCAN COMPOSITIONS AT VARIOUS SALINITIES | March 2020 | June 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16645027 | MULTI-TARGET ANTIMICROBIAL COMPOSITIONS COMPRISING CHITOSAN | March 2020 | June 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16642329 | PROCESS FOR PURIFYING SIALYLATED OLIGOSACCHARIDES | February 2020 | October 2023 | Allow | 44 | 4 | 1 | Yes | No |
| 16798065 | CARBOXYLATED DERIVATIVES OF GLYCOSAMINOGLYCANS AND USE AS DRUGS | February 2020 | March 2022 | Allow | 25 | 3 | 1 | Yes | No |
| 16794991 | NOVEL COMBINATION TREATMENT FOR ACUTE MYELOID LEUKEMIA (AML) | February 2020 | June 2021 | Abandon | 16 | 1 | 1 | No | No |
| 16639305 | METHODS FOR HPLC ANALYSIS | February 2020 | September 2023 | Allow | 43 | 2 | 1 | No | No |
| 16781735 | CARBOXYLATED DERIVATIVES OF GLYCOSAMINOGLYCANS AND USE AS DRUGS | February 2020 | February 2022 | Allow | 24 | 2 | 1 | Yes | Yes |
| 16634304 | HEMOSTATIC MATERIAL AND WOUND DRESSING CONTAINING SAME | January 2020 | December 2022 | Abandon | 35 | 3 | 0 | Yes | No |
| 16631454 | USE OF P2Y1 RECEPTOR AND ANTAGONIST THEREOF IN PREVENTION AND TREATMENT OF DEPRESSION AND/OR ANXIETY DISORDER | January 2020 | October 2022 | Abandon | 33 | 2 | 0 | No | No |
| 16733840 | CONJUGATE OF GINSENOSIDE COMPOUND K AND GLYCOL CHITOSAN AND AN ANTI-TUMOR USE THEREOF | January 2020 | September 2020 | Allow | 9 | 1 | 0 | No | No |
| 16723959 | EXPEDIENT SYNTHESIS OF CORE DISACCHARIDE BUILDING BLOCKS FROM NATURAL POLYSACCHARIDES FOR HEPARAN SULFATE OLIGOSACCHARIDE ASSEMBLY | December 2019 | December 2021 | Allow | 23 | 1 | 1 | No | No |
| 16625003 | HYDROGEL-FORMING MULTICOMPONENT FIBER | December 2019 | October 2023 | Allow | 46 | 3 | 0 | Yes | No |
| 16625568 | MOLECULAR OXYGEN AND HYALURONIC ACIDS FOR TOPICAL-VAGINAL USES | December 2019 | April 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16720369 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | December 2019 | December 2020 | Allow | 12 | 1 | 0 | Yes | No |
| 16624830 | COMPOSITION FOR ENHANCING MITOCHONDRIAL FUNCTION | December 2019 | September 2022 | Allow | 33 | 2 | 0 | Yes | No |
| 16717484 | GRAPHENE-CYCLODEXTRIN COMPLEX AND ITS USE IN CORROSION PREVENTION | December 2019 | May 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16622017 | WHITENING COMPOSITION CONTAINING NOVEL QUERCETIN-BASED COMPOUND | December 2019 | December 2021 | Allow | 24 | 0 | 0 | Yes | No |
| 16710711 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | December 2019 | April 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16710301 | METHOD FOR THE MANUFACTURE AND USE OF A BIONIC HYDROGEL COMPOSITION FOR MEDICAL APPLICATIONS | December 2019 | October 2022 | Allow | 34 | 2 | 0 | Yes | No |
| 16620644 | PROCESS FOR THE PREPARATION OF (S,S)-SECOISOLARICIRESINOL DIGLUCOSIDE AND (R,R)-SECOISOLARICIRESINOL DIGLUCOSIDE | December 2019 | August 2022 | Abandon | 32 | 4 | 0 | No | No |
| 16706725 | INTESTINAL BARRIER INTEGRITY | December 2019 | March 2021 | Allow | 16 | 1 | 0 | No | No |
| 16706627 | COMPOSITION COMPRISING HMSS/HMOS AND USE THEREOF | December 2019 | January 2021 | Abandon | 13 | 1 | 0 | No | No |
| 16619789 | DESMOCOLLIN 1 INHIBITORS FOR THE PREVENTION OR TREATMENT OF ATHEROSCLEROSIS | December 2019 | May 2022 | Abandon | 29 | 2 | 1 | No | No |
| 16617763 | A PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METHOTREXATE AND NOVOBIOCIN, AND THE USE OF SAID COMPOSITION IN THERAPY | November 2019 | December 2023 | Allow | 48 | 5 | 1 | Yes | No |
| 16617783 | MOISTURIZING TOPICAL PREPARATION | November 2019 | October 2021 | Allow | 23 | 1 | 0 | No | No |
| 16693738 | Nutritional Compositions Containing An Elevated Level Of Inositol And Uses Thereof | November 2019 | September 2021 | Abandon | 22 | 3 | 0 | No | No |
| 16693978 | PROCESSES FOR PREPARING MACROLIDES AND KETOLIDES AND INTERMEDIATES THEREFOR | November 2019 | March 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16616426 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | November 2019 | March 2023 | Allow | 40 | 3 | 1 | Yes | No |
| 16616374 | HMO Compositions and Methods for Reducing Autism Spectrum Disorder Symptoms | November 2019 | August 2022 | Allow | 33 | 1 | 0 | Yes | No |
| 16616338 | HMO Compositions and Methods for Reducing Detrimental Proteolytic Metabolites | November 2019 | August 2022 | Allow | 33 | 1 | 0 | Yes | No |
| 16691073 | ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN | November 2019 | March 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16615072 | METHOD FOR REDUCING LUNG INFECTION | November 2019 | March 2022 | Allow | 28 | 2 | 0 | Yes | No |
| 16610936 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC RHINOSINUSITIS | November 2019 | April 2022 | Abandon | 29 | 3 | 1 | No | No |
| 16662774 | ALKYL CHITOSAN-GRAPHENE OXIDE COMPOSITE SPONGE AND PREPARATION METHOD AND APPLICATION THEREOF | October 2019 | June 2021 | Allow | 20 | 0 | 1 | Yes | No |
| 16594740 | TREATMENTS FOR RETINAL DISORDERS | October 2019 | July 2020 | Allow | 10 | 1 | 0 | No | No |
| 16500829 | PROCESS FOR PREPARATION OF SUGAMMADEX SODIUM | October 2019 | August 2021 | Abandon | 23 | 1 | 0 | No | No |
| 16592234 | HYDROPHOBICALLY MODIFIED CHITOSAN COMPOSITIONS | October 2019 | December 2021 | Allow | 27 | 2 | 1 | Yes | No |
| 16590235 | BRANCHED POLYMERS | October 2019 | November 2020 | Abandon | 14 | 1 | 0 | No | No |
| 16498529 | INDUSTRIAL-SCALE D-MANNOSE EXTRACTION FROM D-MANNOSE BISULFITE ADDUCTS | September 2019 | March 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16497489 | MULTIVITAMIN COMPOSITION FOR IMPROVING VERBAL FLUENCY, DECREASING PERFORMANCE ANXIETY SYMPTOMS AND METHOD FOR PREPARING SAME | September 2019 | January 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16497133 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | September 2019 | February 2023 | Allow | 41 | 4 | 0 | Yes | No |
| 16492005 | SURFACTANT COMPOUNDS-CLIPS FOR EXTRACTION AND STABILIZATION IN SOLUTION OF MEMBRANE PROTEINS | September 2019 | May 2022 | Allow | 32 | 1 | 0 | No | No |
| 16563394 | COMPOSITION WITH NON-DIGESTIBLE OLIGOSACCHARIDES FOR ATTENUATING NASAL EPITHELIAL INFLAMMATION | September 2019 | October 2021 | Allow | 26 | 3 | 0 | No | No |
| 16489074 | PENTOSAN POLYSULFATE, PHARMACEUTICAL COMPOSITION, AND ANTICOAGULANT | August 2019 | October 2021 | Allow | 25 | 2 | 0 | Yes | No |
| 16489238 | LACTULOSIDE COMPOUNDS AND PREPARATION AND USE THEREOF | August 2019 | August 2022 | Allow | 35 | 3 | 0 | Yes | No |
| 16487831 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING PANCREATIC CANCER, CONTAINING GOSSYPOL AND PHENFORMIN AS ACTIVE INGREDIENTS | August 2019 | May 2021 | Allow | 21 | 2 | 0 | Yes | No |
| 16545470 | SYNTHESIS OF HYPERBRANCHED POLYMETHACRYLATES AND POLYACRYLATES BY A HALOINIMER APPROACH | August 2019 | January 2024 | Allow | 53 | 4 | 0 | Yes | No |
| 16485312 | CROSSLINKED DEXTRAN AND CROSSLINKED DEXTRAN-POLY ALPHA-1,3-GLUCAN GRAFT COPOLYMERS | August 2019 | January 2022 | Allow | 29 | 1 | 1 | No | No |
| 16484004 | SKIN PIGMENTATION INHIBITOR | August 2019 | September 2021 | Allow | 26 | 2 | 0 | No | No |
| 16521237 | METHOD FOR PRODUCING HYPROMELLOSE PHTHALATE | July 2019 | February 2022 | Allow | 30 | 3 | 0 | Yes | Yes |
| 16521253 | METHOD FOR PRODUCING HYPROMELLOSE ACETATE SUCCINATE | July 2019 | January 2022 | Allow | 30 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KRISHNAN, GANAPATHY.
With a 31.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KRISHNAN, GANAPATHY works in Art Unit 1623 and has examined 759 patent applications in our dataset. With an allowance rate of 42.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner KRISHNAN, GANAPATHY's allowance rate of 42.3% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KRISHNAN, GANAPATHY receive 2.32 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by KRISHNAN, GANAPATHY is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -12.6% benefit to allowance rate for applications examined by KRISHNAN, GANAPATHY. This interview benefit is in the 3% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 14.7% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 29.2% of cases where such amendments are filed. This entry rate is in the 43% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 70.3% of appeals filed. This is in the 57% percentile among all examiners. Of these withdrawals, 53.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 77.9% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.3% of allowed cases (in the 81% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.